EUCTR2013-005575-41-GB
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerability up to 2 years in patients with active ankylosing spondylitis - MEASURE 4
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- ovartis Pharma Services AG
- 入组人数
- 350
- 状态
- 进行中（未招募）
- 最后更新
- 7年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •\- Moderate to severe AS
- •\- Prior radiographic evidence according to the Modified NY Criteria (1984\)
- •\- Inadequate response to NSAIDs
- •Other protocol\-definied inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 304
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 20
排除标准
- •\- Pregnancy or lactation
- •\- On\-going infectious or malignant process on a chest X\-ray or MRI
- •\- Previous exposure to IL\-17 or IL\-17R targeting therapies
- •\- Previous exposure to any biological immunomodulating agent excluding TNF antagonists
- •\- Previous cell depleting therapy
- •Other protocol\-definied exclusion criteria may apply.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Study of safety and efficacy of PDR001 in combination with dabrafenib and trametinib in patients with a genetically distinct subtype of unresectable or metastatic melanoma, which is characterised by a mutation in the BRAF genenresectable or metastatic BRAF V600 mutant melanomaMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-002794-35-ITOVARTIS PHARMA AG538
进行中（未招募）
不适用
A comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomasCD30-positive mature T-cell lymphomasMedDRA version: 14.1Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002751-42-ITSeattle Genetics, Inc.300
进行中（未招募）
1 期
16-week efficacy and 2-year safety, tolerability and efficacy of secukinumab in participants with active ankylosing spondylitisAnkylosing SpondylitisMedDRA version: 17.1Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2013-005575-41-ESovartis Farmacéutica, S.A.324
进行中（未招募）
1 期
Study of efficacy and safety of canakinumab in combination with docetaxel in subjects with non-small cell lung cancers as a second or third line therapy.on-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002480-26-ITOVARTIS PHARMA AG245
进行中（未招募）
1 期
Study of efficacy and safety of canakinumab in combination with docetaxel in subjects with non-small cell lung cancers as a second or third line therapy.on-small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002480-26-ESovartis Farmacéutica S.A.244